- NorthX Biologics and Demeetra have formed a strategic collaboration combining a GS (−/−) CHO cell line platform with integrated cell line development, master cell banking, and GMP manufacturing services.
- The partnership aims to reduce technical risk, streamline tech transfer, and shorten timelines to IND-enabling and clinical milestones.
NorthX Biologics and Demeetra have announced a strategic collaboration to provide an integrated solution spanning advanced cell line development (CLD), master cell banking (MCB), and GMP manufacturing services. The offering combines a GS (−/−) CHO cell line platform with full freedom to operate and no additional IP-related costs, designed to help biotech companies reach IND-enabling and clinical milestones more efficiently.
The collaboration integrates Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ GMP production capabilities, process scale-up expertise, including aseptic fill and finish, and regulatory-grade quality systems. The companies state that the model is structured to minimize tech-transfer delays, reduce the risk of cell line rebuilds, and eliminate the need to re-qualify processes when transitioning to manufacturing.
The joint solution is intended to address common challenges in early biologics development, including long development cycles, technical bottlenecks, and funding-sensitive delays. By coordinating CLD and GMP manufacturing under a single framework, the companies aim to provide a streamlined path from gene to clinical material suitable for IND and Phase I studies.
“Biotech companies no longer need to choose between best-in-class cell line development and proven GMP execution. Our collaboration with Demeetra provides an optimal solution for development of biologics.”
Janet Hoogstraate, CEO of NorthX Biologics
The companies stated that the collaboration reflects a shared commitment to reducing fragmentation in early biologics development by integrating genome engineering, upstream processing, and GMP execution within a coordinated development pathway.
